一项韩国回顾性分析揭示PIK3CA基因突变在原发灶与转移灶间总体一致率达87.8%。 乳腺癌作为全球女性中最常见的恶性肿瘤 [1] ，其早期诊断与治疗对 ...

Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA ...

New research indicates that a drug called Inavolisib is effective at treating a type of metastatic breast cancer with a ...